期刊
CURRENT PHARMACEUTICAL DESIGN
卷 22, 期 9, 页码 1161-1176出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612822666151216150238
关键词
Nanoparticles; nanomedicine; peptides; diabetes; insulin; incretin; GLP-1
资金
- European Union Seventh Framework Programme (FP7) [281035]
Over the last years, the interest of the pharmaceutical industry in the use of therapeutic peptides in diabetes treatment has been increased. However, these are restricted to parenteral administration. In order to mimic the natural physiological response, many efforts have been made towards oral peptide delivery in diabetes treatment. This review article aims to give an overview on the progress in the nanomedicine field towards the design and optimization of nanoparticle-based drug delivery systems capable of overcoming the harsh gastrointestinal environment and achieving an adequate bioavailability following oral administration. The reported data clearly illustrate the promise of nanomedicine for antidiabetic oral peptide delivery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据